Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stapokibart (CM310) in Moderate to Severe Asthma
NCT05761028Phase 3Recruiting
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Apr 2023
- Primary completion
- May 2032
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of stapokibart in asthma, sponsored by CSPC ZhongQi Pharmaceutical Technology. Started Apr 2023; status: recruiting.
02
Drugs
stapokibart
03
Conditions
asthma
Beyond the preview
Go deeper on NCT05761028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05761028.